'Huge Need' For Neurotoxicity Biomarkers In Drug Development, FDA's Woodcock Says
Executive Summary
"Perfect storm" makes it difficult to develop safety biomarkers, Woodcock tells US FDA workshop, citing lack of body charged with developing them and greater evidence required for their qualification.